Misplaced Pages

Atumelnant: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactivelyNext edit →Content deleted Content addedVisualWikitext
Revision as of 06:45, 27 December 2024 editBoghog (talk | contribs)Autopatrolled, Extended confirmed users, IP block exemptions, New page reviewers, Pending changes reviewers, Rollbackers, Template editors137,699 edits created drug stubTag: nowiki added  Revision as of 09:22, 27 December 2024 edit undoGraeme Bartlett (talk | contribs)Administrators249,639 edits added Category:Ethoxy compounds using HotCatNext edit →
Line 123: Line 123:
] ]
] ]
]

Revision as of 09:22, 27 December 2024

Pharmaceutical compound
Atumelnant
Clinical data
Other namesCRN04894
Identifiers
IUPAC name
  • N-octan-3-yl]-6-(2-ethoxyphenyl)-3-piperazin-1-yl]pyridine-2-carboxamide
CAS Number
PubChem CID
IUPHAR/BPS
UNII
Chemical and physical data
FormulaC33H42F3N5O3
Molar mass613.726 g·mol
3D model (JSmol)
SMILES
  • CC1CN(CCN1C2=C(N=C(C=C2)C3=CC=CC=C3OCC)C(=O)N4CN5CCC4CC5)C(=O)C6(CCC6)C(F)(F)F
InChI
  • InChI=InChI=1S/C33H42F3N5O3/c1-3-23-20-40(31(43)32(14-7-15-32)33(34,35)36)18-19-41(23)27-11-10-25(24-8-5-6-9-28(24)44-4-2)37-29(27)30(42)38-26-21-39-16-12-22(26)13-17-39/h5-6,8-11,22-23,26H,3-4,7,12-21H2,1-2H3,(H,38,42)/t23-,26-/m1/s1
  • Key:QJRFBKYETDVAJQ-ZEQKJWHPSA-N

Atumelnant (CRN04894) is an investigational new drug developed by Crinetics Pharmaceuticals for the treatment of adrenocorticotropic hormone (ACTH)-dependent endocrine disorders. It is a selective antagonist of the melanocortin type 2 receptor (MC2R), also known as the ACTH receptor, which is primarily expressed in the adrenal glands. Atumelnant is being evaluated to treat conditions such as congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing's syndrome caused for example by pituitary adenomas.

References

  1. "Atumelnant (CRN04894)". crinetics.com.
  2. Varlamov EV, Gheorghiu ML, Fleseriu M (December 2024). "Pharmacological management of pituitary adenomas - what is new on the horizon?". Expert Opinion on Pharmacotherapy. doi:10.1080/14656566.2024.2446625. PMID 39718553.
Stub icon

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

Categories: